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OBJECTIVES: CLL is a common form of leukaemia associated
with symptoms of tiredness, night sweats, weight loss, anaemia
and infection. The objective of this study was to measure the
comparative utility of eight disease states describing two ﬁrst line
treatments (MabCampath, chorambucil) and the progression-
free and progressive stages of CLL following ﬁrst, second and
ﬁnal lines of therapy. METHODS: In order to obtain societal
preferences, we conducted a utility study in the UK with 60
members of the general public using the Time Trade-Off (TTO)
method. The interviews were conducted face-to-face by trained
interviewers using a TTO scale with a 10 year duration period. A
Visual Analogue Scale (VAS) (0 being death and 100 being full
health) was also included. Information on the condition and
health states were developed using literature, in-depth interviews
and validation with specialist nurses and a specialist physician.
RESULTS: The mean utility scores according to the TTO were:
progression-free after ﬁrst-line therapy; 0.777, progressive after
ﬁrst-line therapy; 0.540, progression-free after second-line
therapy; 0.650, progressive after second-line therapy; 0.470,
progression-free after ﬁnal-line therapy; 0.428 and progressive
after ﬁnal-line therapy; 0.279. The mean utility on ﬁrst-line treat-
ment was 0.619 for MabCampath and 0.623 for chlorambucil.
The VAS scores had similar values. CONCLUSIONS: In conclu-
sion, there was gradual decline in the utility score after each
subsequent line of therapy for patients in progression-free states
and for patients in progressive states. Utility decreased when
patients moved from progression-free to progressive states after
each line of therapy. These values can be used in cost-utility
analyses of treatment pathways associated with CLL.
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OBJECTIVES: To compare patient reported quality of life in
cancer patients on opioid therapy with and without constipation.
METHODS: Patients with a diagnosis of cancer, receiving
opioids from all public pharmacies in The Netherlands, were
recruited by a pharmacy worker to complete a generic question-
naire about opioid use and constipation and the EuroQoL-5-
Dimensions questionnaire (EQ-5D) about generic Quality of Life
(QoL). Patients were classiﬁed as having constipation or not
based on self-reported bothersome side effect of the opioid and
use of laxatives. EQ-5D index scores were compared with Wil-
coxon Two-group test. RESULTS: A total of 113 patients using
opioids from 170 pharmacies returned the questionnaires.
Seventy-ﬁve (66%) of the cancer patients were classiﬁed as
having constipation. Patients with and without constipation were
similar with respect to age (mean  standard deviation
66.1  9.8 and 63.8  12.6, respectively), gender (44% and
50% males, respectively) and type of opioid (most frequently
oxycodone, fentanyl and morphine preparations in both groups).
Patients with constipation more often reported problems with
Pain (95% versus 92%) and Anxious/depressed Mood (52% vs.
42%), but less often with Self care (52% vs. 58%) than patients
without constipation. The median [25th–75th percentile] EQ-5D
index score among patients with constipation was lower com-
pared to those without constipation (0.39 [0.19–0.69] vs. 0.63
[0.30–0.78], p = 0.10). CONCLUSIONS: Constipation in cancer
patients using opioids has a substantial impact on patient’s
quality of life. Alleviation of constipation symptoms might help
improve patient reported quality of life.
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OBJECTIVES: To carry out a cross-cultural adaptation into
Spanish of the UCLA-PCI questionnaire and to validate a
reduced version. METHODS: Firstly, forward-backward trans-
lations of the UCLA-PCI were made by two native (English and
Spanish) translators and integrated into a preliminary version by
an expert panel (two urologists and one radiologist). Compre-
hension of items was analyzed by 15 prostatic cancer (PC)
patients by using a 4 levels likert scale. As a result, an initial
version (UCLA-PCI 1.0) was reached by consensus. Next, 50 PC
patients who had received treatment (radiotherapy or prostatec-
tomy) 3 years before answered both the UCLA-PCI 1.0 and the
generic HRQoL questionnaire SF-12 Health Survey. Exploratory
factorial analysis -FA-, item-total correlations and conﬁrmatory
FA (promax oblique rotation) were applied to reduce the UCLA-
PCI 1.0 into a 4 items scale (UCLA-PCI-brief). Internal consis-
tency (Cronbach’s a), feasibility and convergent validity
(Spearman correlation with SF-12 and non parametric test for 2
independent samples, according to TNM tumor stage) were
assessed. RESULTS: Internal consistency was high in UCLA-PCI
1.0 (0.856) and acceptable in UCLA-PCI-brief (0.731). UCLA-
PCI 1.0 FA showed the same constructs that the original (urinary,
bowel and sexual symptoms—function and bother). UCLA-PCI-
brief FA revealed 3 functional dimensions: urinary (2 items;
56.16 of variance explained), bowel (1 item, 21%), intestinal (1
item, 15.28%). Moreover, correlations between UCLA-PCI–brief
and SF-12 Mental and Physical Summaries Components were
respectively: urinary (0.31 and 0.38; p > 0.05), intestinal (0.29
and 0.634; p < 0.05) and sexual (0.04 and 0.33; p > 0.05).
Finally, signiﬁcant differences were found in the UCLA-PCI
scores between patients with a more favorable PC stage and
patients with a worse prognosis. CONCLUSIONS: The Spanish
version of the UCLA-PCI maintains the same structure as the
original. An item reduced version (UCLA-PCI-brief) with
adequate properties has been developed.
PCN82
TESTINGTHE MEASUREMENT EQUIVALENCE OF PAPER
AND INTERACTIVEVOICE RESPONSE (IVR) VERSIONS OF
THE EQ-5D
Lundy JJ, Coons SJ
University of Arizona,Tucson, AZ, USA
OBJECTIVES: Electronic data capture technologies, such as
interactive voice response (IVR) systems, are emerging as impor-
tant alternatives for collecting patient-reported outcomes data.
The objective of this study was to assess the measurement equiva-
lence of an IVR version of the EQ-5D with the original paper
version. METHODS: This study utilized a crossover design with
subjects randomly assigned to one of two assessment orders: 1)
paper then IVR or 2) IVR then paper. A convenience sample of
in-treatment outpatient cancer clinic patients (n = 139) were
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asked to complete each assessment two days apart. The analyses
tested for mean differences (repeated measures ANOVA) and
reliability (intraclass correlation coefﬁcient [ICC]) to assess mea-
surement stability over time. Equivalence of the means was estab-
lished if the 95% conﬁdence interval (CI) of the mean difference
was within the minimally important difference (MID) interval:
-0.035 to .035 for the index and -3 to 3 for the EQ VAS.
Adequacy of the ICC was established by comparing the ICC 95%
lower CI with a critical value of 0.70. RESULTS: The per pro-
tocol analysis included 109 subjects for the EQ VAS and 113
subjects for the index. For the EQ-5D index, the means (SD) of
the paper and IVR administrations were 0.790 (0.172) and 0.800
(0.180), respectively. The 95% CI of the mean difference was
-0.024 to 0.006, which was within the equivalence interval. The
ICC was 0.894 (95% lower CI 0.857), signiﬁcantly different
from 0.70. For the EQ VAS, the means (SD) were 72.0 (19.7) for
paper and 74.1 (19.8) for IVR. The 95% CI of the mean differ-
ence was -3.784 to -0.484, partially within the equivalence
interval. The ICC was 0.897 (95% lower CI 0.859) also signiﬁ-
cantly different from 0.70. CONCLUSIONS: This analysis pro-
vides evidence that the EQ-5D scores on the IVR version were
equivalent to those obtained on the original paper version.
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OBJECTIVES: Cancer-related fatigue (crF) is a frequently
reported complaint in cancer patients and survivors. The Perform
Questionnaire (PQ) is a recently validated 12-item scale to assess
perceptions and beliefs about crF throughout the dimensions
‘Physical limitations’, ‘Activities of daily living’, ‘Beliefs and atti-
tudes’. This study aims to explore the performance of different
ways for identifying stable patients in the assessment of test-retest
reliability. METHODS: Patients with a moderate level of crF
participated in an observational and longitudinalmulti-centre. PQ
and a 100 mm horizontal visual analogue scale for fatigue inten-
sity (VAS) were administered at inclusion and 3 months later.
Stability concerning crF was deﬁned as either: 1) absence of
self-reported health change, using a standard self-administered
health status item (HSI) at the second visit on a Likert-type ordinal
scale with 13 response options, or 2) Fatigue VAS score change
between visits <5 mm. Test-retest reliability (Intraclass correlation
coefﬁcient, ICC) was assessed for the PQ overall and for the three
dimension scores, using each method 1 and 2.RESULTS: Baseline
sample characteristics (n = 437) were: 60.5% women, mean age
59.1 years, an average of 2.21 years since diagnosis, 33.6% breast
cancer, 54.7% with metastasis, Karnofsky mean score 80.9, and
29.1% with anaemia. ICC values obtained using the method 1
(n = 58) didn’t reach the standard value recommended (0.70) for
the overall (0.68) neither the dimension scores (0.52–0.68), while
ICC values obtained using themethod 2 (n = 64) were satisfactory
and reached the standards accepted for this psychometric proper-
tie assessment (0.83 for the overall score and ranging between
0.77 and 0.84 for the three dimension scores). CONCLUSIONS:
Patient-perspective is a relevant approach in the assessment of the
psychometric properties of the patient-oriented health outcomes
measures. The performance and adequacy of different patient-
perspective criteria can conduct to different conclusions concern-
ing speciﬁc psychometric properties.
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OBJECTIVES: Among patients with cancer and other diseases,
pain is a common experience that can negatively impact daily
living. It is unclear whether pain experiences and their impact are
diagnosis-speciﬁc or shared across conditions. We examined
whether the United States general population-based PROMIS
Pain Impact item bank can be used for measuring cancer pain,
and the relationship between pain experience and pain impact.
METHODS: PROMIS Pain Impact items included in ﬁeld testing
with oncology populations were selected through expert consen-
sus. Multidisciplinary clinical input was obtained to ensure
content coverage and the relevance of PROMIS pain items to
cancer. Items’ psychometric properties were reviewed when
applicable. As a result, PROMIS-Ca Pain Impact consisted of 36
items across 3 areas: physical, emotion and social. The sample
included 529 cancer patients (74% female, 82% White, mean
age = 56). Analyses included item scalability (item-scale correla-
tion >0.3), unidimensionality (exploratory and conﬁrmatory
factor analysis, and multidimensional scaling), and IRT model ﬁt
(S2-G2 & S2-X2). RESULTS: All 36 PROMIS-Ca Pain Impact
items met preset analysis criteria to form a unidimensional item
bank. Additional analyses showed that scores from Pain Impact
were signiﬁcantly correlated with Pain Quality items assessing
pain intensity (r = 0.56), frequency (r = 0.58) and duration
(r = 0.64), and could signiﬁcantly differentiate patients with dif-
ferent degrees of neuropathic pain, F(4527) = 37.4, p < 0.0001,
emotional distress as measured by two items F(4472) = 122.53,
p < 0.001, and F(4453) = 74.94, p < 0.001. Similar results were
found regardless of whether patients based their responses on
their “worst” or “least” pain experience. CONCLUSIONS:
PROMIS-Ca Pain is a psychometrically-sound and clinically
meaningful measure for cancer patients. It is correlated with
patients’ pain experience. Our next step is to examine whether
the same conclusion can be made with other disease groups.
Ultimately, a statistical cross-walk of pain scores could be created
to enable the comparison of pain scores between disease groups.
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OBJECTIVES: Analyses of patients’ preferences about their
therapies are a prerequisite for shared decision making, but are
still not widely performed. This study elaborates the importance
of treatment aspects in the eyes of multiple myeloma (MM)
patients using direct assessment and Discrete-Choice-
Experiments (DCE). METHODS: After a literature review we
conducted focus groups with 6–8 MM patients to collect the
most important therapy aspects. Then, patients answered an
online or paper-pencil questionnaire which asked for sociodemo-
graphic data, self-rated-health (SF12v2 variation) and patients’
preferences about therapy. The latter were assessed using direct
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